Latest Headlines

Does Anemia Protect Children From Malaria?

It is well known that sickle cell trait can protect carriers from developing malaria; yet iron deficiency anemia offers a greater protective effect against malaria than sickle cell trait, according to research published in...

Online Exclusive

Leading Cancer Researcher Failed to Disclose Industry Funding

An investigation by The New York Times and ProPublica has found that José Baselga, MD, PhD, chief medical officer at Memorial Sloan Kettering Cancer...

AACR Releases Cancer Progress Report

Bipartisan commitment to investing in biomedical science has led to innovations in cancer research, according to the American Association for Cancer Research’s (AACR’s) recently...

Cover Story

Predatory Publishing: The Dark Side of the Open-Access Movement

In October 2016, we dived deep into the open-access (OA) movement – a publishing model in which a scientific article is made freely available – examining the benefits and the drawbacks of this approach to research (“Public Access: The Pros and Cons of Open-Access Publishing”). This month, we take a closer look at another, darker side of scientific publishing: predatory publishing. This segment of the OA publishing movement is characterized by publishers that “unprofessionally exploit” the gold OA model (in which the final version of a manuscript is made freely available on publication), primarily for profit, according to Jeffrey Beall, MSLS, one of the most vigilant watchdogs of predatory publishing, and operator of the website Scholarly Open Access. Sometimes called “vanity presses,” these entities publish practically any materials that come their way, as long as authors are willing to pay a submission and publication fee. Critics – and they are legion...

Clinical News

Latest Videos

Pulling Back the Curtain: Angela Thomas, OBE, PhD

Hear more from our interview with Dr. Thomas, where she talks about "converting" trainees to pediatric hematology and offers career advice for early-career hematologists.

Pulling Back the Curtain: Allison Rosenthal, DO

Hear more from our interview with Dr. Rosenthal, where she talks about the best career advice she's ever received and the best (and worst) parts of...
video

Expanding Acalabrutinib to Waldenström Macroglobulinemia

Roger Owen, MRCP, MRCPath, MD, presents phase II data of the selective Bruton tyrosine kinase inhibitor, which showed “exceptional response rates” in both treatment-naïve...
video

Weekly Carfilzomib Dosing Superior to Twice-Weekly Dosing

James Berenson, MD, discusses results from a trial evaluating less-frequent dosing of carfilzomib for patients with myeloma. Once-weekly dosing was superior, but the mechanisms...

On Location

From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL

During their presentations, MHM speakers will be asking the audience how they would respond to...

From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal Residual Disease

During their presentations, MHM speakers will be asking the audience how they would respond to...

From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera

During their presentations, MHM speakers will be asking the audience how they would respond to...

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology...

Umbralisib Demonstrates Safety, Efficacy for Patients With Kinase Inhibitor–Intolerant CLL

According to a report presented at the 23rd Congress of the European Hematology Association, the...

Tagraxofusp: A New Option for Blastic Plasmacytoid Dendritic Cell Neoplasm?

Treatment with tagraxofusp, an anti-CD123 targeted agent previously known as SL-401, appeared to be safe...
Advertisement

Sign Up for our enewsletter!

Subscribe to our newsletter to receive the latest news, updates and online exclusive content.

8,802FollowersFollow
6,079SubscribersSubscribe

Leading Cancer Researcher Failed to Disclose Industry Funding

An investigation by The New York Times and ProPublica has found that José Baselga, MD, PhD, chief medical officer at Memorial Sloan Kettering Cancer...

AACR Releases Cancer Progress Report

Bipartisan commitment to investing in biomedical science has led to innovations in cancer research, according to the American Association for Cancer Research’s (AACR’s) recently...

Senate Reviewing Legislation Addressing Opioid Epidemic

The U.S. Senate has reached an agreement on a comprehensive bill addressing the opioid epidemic, following the lifting of a legislative hold. The bipartisan...

Major Hospitals Launch Generic Drug Company

Responding to ongoing drug shortages and high prices, several major hospital groups in the U.S. have announced a partnership to manufacture generic drugs. The new...

Theranos Shutting Down Amid Fraud Allegations

In a letter to investors, the CEO of Theranos announced that the blood-testing company is preparing to shut down. Theranos has faced a U.S....